[Ip-health] Insulin4all Demonstration at Eli Lilly Headquarters

Fran Quigley fwquigley at gmail.com
Mon Sep 11 08:11:55 PDT 2017


Thanks to chief organizer T1International and supporting organizations People of Faith for Access to Medicines, Public Citizen, and Patients for Affordable Drugs, an important #insulin4all action was conducted at Eli Lilly headquarters on Saturday. 

Forty-plus people attended, the majority of whom were persons living with diabetes or their family members, some traveling from as far away as Pennsylvania. It was a strikingly passionate group, armed with homemade signs that demonstrated deep frustration over the skyrocketing price of insulin.  (One news station included some photos, http://www.theindychannel.com/news/photos-protesters-demand-eli-lilly-lower-insulin-costs#id0 . There are many more photos online connected to the insulin4all action Facebook page, and the livestream video is archived on the T1I and PFAM Facebook pages.)

The action earned front-page above-the-fold coverage in both the Indianapolis Star and Indianapolis Business Journal, with the Star article also reprinted in USA Today, and coverage by several local TV and radio stations, multiple diabetes-oriented online outlets, etc. For those who could not attend, T1I led a companion call-in Day of Action to lawmakers on the day before the live demonstration. 

This was a patient-led action that included moving testimony from persons with diabetes and a statement from the mother of a recently deceased young man who died of diabetic ketoacidosis after rationing insulin because he could not afford the price of full doses. 

Before the demonstration, a representative from Eli Lilly reached out to ask for a meeting with representatives of T1International and People of Faith for Access to Medicines to discuss insulin pricing, and we have agreed to do so. That meeting has not yet been arranged. 

The type 1 diabetes community and supporting organizations are discussing next steps, including plans to conduct similar demonstrations outside of Sanofi and Novo Nordisk facilities soon.





More information about the Ip-health mailing list